KRAS and neoplasm: There was no difference in SLC8B1 mRNA levels between male and female tumor tissues (Figure 1—figure supplement 1A) and between patients bearing mutated and normal proto-oncogene KRAS and phosphoinositide 3-kinases (PI3K) (Figure 1C).